Akums Drugs and Pharmaceuticals has started FY27 on a strong note, reporting a 13.9% year-on-year rise in operating revenue and a sharp improvement in profitability for the quarter ended June 30, 2026.
The company reported operating revenue of Rs. 1,167 crore in Q1 FY27, up from Rs. 1,024 crore in the year-ago quarter. EBITDA rose 35.4% YoY to Rs. 175 crore, pushing the EBITDA margin to 15% from 12.6% a year earlier.
Profit after tax (PAT) surged to Rs. 101 crore, compared with Rs. 65 crore in Q1 FY26, while PAT margin expanded to 8.4% from 6.2%.
The company’s CDMO business remained the main growth engine, with revenue climbing to Rs. 964 crore from Rs. 813 crore in Q1 FY26. CDMO EBITDA rose 36.8% YoY to Rs. 163 crore from Rs. 119 crore, aided by continued volume growth and improved API prices.
Akums also reported sequential improvement in profitability. EBITDA rose from Rs. 152 crore in Q4 FY26 to Rs. 175 crore in the June quarter, while PAT increased from Rs. 81 crore to Rs. 101 crore.
Commenting on the results, Sanjeev Jain, Managing Director, said, "FY27 has begun on a strong and encouraging note. The consistent performance of CDMO showcases healthy demand environment as well as our clients' trust in Akums as the preferred manufacturing partner."
Sandeep Jain, Managing Director, added, "We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable growth in the years ahead."
